China-based Legend Biotech Corporation (NASDAQ: LEGN) has formed a partnership with Trinity College Dublin and Saint James’s Hospital in Ireland to develop 3D models for exploring chimeric antigen receptor T-cell (CAR-T) therapies in solid tumors. This collaboration, focusing on lung, colorectal, and gastric cancers, aims to create three types of tumor 3D models to identify new therapeutic targets and screen novel CAR-T cell therapies.
Collaboration Details
The 18-month project will be conducted at the Trinity Translational Medicine Institute, led by Dr. William McCormack and Legend Ireland’s Vice Director of Business Development and Operations, Dr. Sharon O’Neill. The institute is Ireland’s sole clinical center capable of CAR-T and stem cell transplantation.
Institutional Strengths
Trinity College Dublin ranks in the top 1% globally among medical and biological research institutions. Saint James’s Hospital, a major teaching hospital affiliated with Trinity College Dublin, provides specialized cancer care services.
Legend Biotech’s Pipeline
Legend Biotech is co-developing Carvykti (ciltacabtagene autoleucel), a BCMA-targeted CAR-T therapy for multiple myeloma, with Janssen. The therapy has received FDA approval and conditional EU approval. The company is also advancing other CAR-T therapies for blood and solid tumors.-Fineline Info & Tech
